3D-BrachyView: A 3D Real-time Virtual Reality Intra-operative Quality Assurance System For Brachytherapy
Funder
National Health and Medical Research Council
Funding Amount
$359,105.00
Summary
3D-Brachyview aims to bring 3D virtual reality into the Quality Assurance and training of physicists in prostate cancer brachytherapy. The 3D simultaneous visualisation of the position of the seeds implanted, the actual shape and position of the prostate, and the expected treatment plan, will help doctors to deliver the best treatment possible.
Development Of Effective Biomarkers For The Diagnosis And Prognosis Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,062,585.00
Summary
Every year ~20,000 Australian men are diagnosed with prostate cancer and more than 3,000 die of this disease. The current PSA test for the diagnosis of prostate cancer is not specific and this can result in incorrect diagnosis, unnecessary biopsies and lead to wrong treatments. We have discovered a novel change in the biology of prostate cancer. We will use this information to develop new tests for prostate cancer, which provide early accurate detection and can predict disease progression.
BrachyVision: A Novel Multipurpose Probe For In-body Radiation Imaging And Dosimetry.
Funder
National Health and Medical Research Council
Funding Amount
$532,627.00
Summary
BrachyVision is an in-body imaging and dosimetry system to assist physicians in providing efficient and optimized permanent seed implant brachytherapy cancer treatment. The system allows intra-operative preplanning, image guided treatment, post implant verification and direct rectal dosimetry. It represents a major advance in clinical technology that can improve quality of life of prostate cancer patients and, through reduced post treatment complications, lead to significant health cost savings.
Novel Prostate Cancer Target For Diagnosis, Imaging, Detection Of Recurrence And Response To Therapy
Funder
National Health and Medical Research Council
Funding Amount
$731,497.00
Summary
This project will generate the critical proof of concept to justify clinical development of a novel biomarker in prostate cancer which would bring significant benefit in terms of differential diagnosis of aggressive disease. The biomarker will be assessed for a functional role in prostate cancer and potential as a therapeutic target and use as a imaging agent in for monitoring disease progression and response to therapy. These investigations will be extended to other common solid tumours.